Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23309243 | 0.84 | CA12 (0.45) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22070494 | 0.84 | CA12 (0.45) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20525006 | 0.83 | PPARG (0.39) | SLC6A2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20525004 | 0.83 | PPARG (0.39) | SLC6A2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15430483 | 0.81 | DEGS1 (0.50) | IDO1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL15430481 | 0.81 | DEGS1 (0.50) | IDO1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL14097153 | 0.81 | ALDH1A1 (0.63) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL16229142 | 0.81 | DEGS1 (0.50) | IDO1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL1100407 | 0.81 | DEGS1 (0.50) | IDO1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL2359242 | 0.80 | MAPT (0.56) | SLC6A2SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | IDO1 1607/4885SLC6A2 357/4885SLC6A4 194/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | IDO1 660/4885SLC6A2 42/4885SLC6A4 50/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | IDO1 660/4885SLC6A2 42/4885SLC6A4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.